Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 1.00 |
| ▸ | SRC | P12931 | 8/20 | 1.00 |
| ▸ | BRAF | P15056 | 5/20 | 0.62 |
| ▸ | RIPK2 | O43353 | 5/20 | 0.61 |
| ▸ | EGFR | P00533 | 1/20 | 0.61 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.61 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.61 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CDC7 | O00311 | 1/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.42 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.37 |
| ▸ | GABRP | O00591 | 1/20 | 0.37 |
| ▸ | GABRD | O14764 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14833637 | 0.90 | KDR (1.00) | KDRSRCBRAFRIPK2EGFR | |
| SCHEMBL14833707 | 0.83 | KDR (0.71) | KDRSRCBRAFRIPK2EGFR | |
| SCHEMBL14833703 | 0.76 | SRC (1.00) | KDRSRCBRAFRIPK2L3MBTL1 | |
| SCHEMBL14833731 | 0.76 | KDR (0.62) | KDRSRCBRAFRIPK2EGFR | |
| SCHEMBL14839289 | 0.76 | KDR (1.00) | KDRSRCBRAFRIPK2EGFR | |
| SCHEMBL27435285 | 0.75 | SRC (0.60) | KDRSRCBRAF | |
| SCHEMBL7965709 | 0.73 | SRC (0.58) | KDRSRCRIPK2L3MBTL1CCNE1 | |
| SCHEMBL6208048 | 0.73 | KDR (0.57) | KDRSRCBRAFRIPK2EGFR | |
| SCHEMBL6208684 | 0.73 | SRC (0.57) | KDRSRCL3MBTL1CCNE1CDK2 | |
| SCHEMBL6209612 | 0.73 | SRC (0.57) | KDRSRCRIPK2L3MBTL1GABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9416123-B2 | Kinase modulators for the treatment of cancer | SYNOVO GMBH (DE) | 2016-08-16 | — | — | US | claimed |
| US-9416123-B2 | Kinase modulators for the treatment of cancer | SYNOVO GMBH (DE) | 2016-08-16 | — | — | US | disclosed |
| US-9416123-B2 | Kinase modulators for the treatment of cancer | SYNOVO GMBH (DE) | 2016-08-16 | — | — | US | disclosed |
| US-9416123-B2 | Kinase modulators for the treatment of cancer | SYNOVO GMBH (DE) | 2016-08-16 | — | — | US | disclosed |
| US-20140336225-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| US-20140336225-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| US-20140336225-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| WO-2013046041-A1 | PYRIDINYLPYRAZOLES FOR USE AS KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013046041-A1 | PYRIDINYLPYRAZOLES FOR USE AS KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336225-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | DCK, MAP3K2, MAP3K19 | KDR 652/4885SRC 124/4885BRAF 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.